ReviewJournal of neuro-oncology2004
Molecular pathogenesis of oligodendroglial tumors.
Review in Journal of neuro-oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 116 citations in OpenAlex.
- Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.Brain pathology (Zurich, Switzerland) · 2008Trial
- Review
- Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.Metabolic brain disease · 2023Review
- Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.Neuro-oncology · 2019Article
- Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.Journal of neuro-oncology · 2014Article
- 1p/19q testing has no significance in the workup of glioblastomas.Neuropathology and applied neurobiology · 2013Article
- Progress on molecular biomarkers and classification of malignant gliomas.Frontiers of medicine · 2013Review
- Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH.Journal of neuro-oncology · 2012Article
- Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.Neuropathology and applied neurobiology · 2012Review
- Long-term epilepsy-associated tumors.Brain pathology (Zurich, Switzerland) · 2012Review
- Detection of 1p19q deletion by real-time comparative quantitative PCR.Biomarker insights · 2012Article
- Biology, genetics and imaging of glial cell tumours.The British journal of radiology · 2011Review
- The nature and timing of specific copy number changes in the course of molecular progression in diffuse gliomas: further elucidation of their genetic "life story".Brain pathology (Zurich, Switzerland) · 2011Article
- Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles.Journal of neuro-oncology · 2011Article
- Molecular diagnostics of gliomas: state of the art.Acta neuropathologica · 2010Review
- Molecular neuropathology of gliomas.International journal of molecular sciences · 2009Review
- Article
- Low-grade gliomas in older patients: a retrospective analysis of prognostic factors.Journal of neuro-oncology · 2008Article
- Two metachronous tumors induced by radiation therapy: case report and review of the literature.Journal of neuro-oncology · 2008Article
- Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy.Brain pathology (Zurich, Switzerland) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on their histopathological appearances, most diffusely infiltrative gliomas can be classified either as astrocytic tumors (As), pure oligodendroglial tumors (Os) or mixed oligoastrocytic tumors (OAs). The latter two may be grouped together as oligodendroglial tumors (OTs). The distinction between As and OTs is important because of the more favorable clinical behavior of OTs. Unfortunately, the histopathological delineation of OAs, Os and As can be difficult because of vague and subjective histopathological criteria. Over the last decade, the knowledge on the molecular genetic background of OTs has drastically increased. This review provides an overview of molecular genetic aberrations in OTs and discusses the pathobiological and clinical significance of these aberrations. In contrast to As, OTs frequently show frequent loss of heterozygosity on chromosome arms 1p and 19q. Since these aberrations are significantly correlated with clinically relevant parameters, such as prognosis and chemosensitivity, and given the difficulties in histopathological typing and grading of glial tumors, genetic testing should be included in routine glioma diagnostics. It is to be expected that the identification of the relevant tumor suppressor genes located on 1p and 19q will lead to more refined genetic tests for OTs. Furthermore, as microarray technology is rapidly increasing, it is likely that clinically relevant markers for OTs will be identified on other chromosomes and need to be included into routine glioma diagnostics as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.